EP 4340943 A1 20240327 - USES OF ANTI-ICOS ANTIBODIES
Title (en)
USES OF ANTI-ICOS ANTIBODIES
Title (de)
VERWENDUNGEN VON ANTI-ICOS-ANTIKÖRPERN
Title (fr)
UTILISATIONS D'ANTICORPS ANTI-ICOS
Publication
Application
Priority
- US 202163190016 P 20210518
- EP 2022063450 W 20220518
Abstract (en)
[origin: AU2022276349A1] Therapeutic use and dosing regimen of anti-ICOS antibodies or antigen-binding fragments thereof for modulating the ratio between regulatory T cells and effector T cells, stimulating the immune system of patients, and/or treating tumours or cancers, as monotherapy or combination therapy, e.g., with anti-PD-L1 antibodies or antigen-binding fragments thereof.
IPC 8 full level
A61P 35/00 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP IL KR)
A61P 35/00 (2017.12 - EP IL KR); C07K 16/2818 (2013.01 - EP IL KR); C07K 16/2827 (2013.01 - EP IL KR); A61K 2039/505 (2013.01 - EP IL); A61K 2039/507 (2013.01 - EP IL KR); A61K 2039/545 (2013.01 - EP IL KR); A61K 2039/57 (2013.01 - EP IL KR); C07K 2317/74 (2013.01 - EP IL KR); C07K 2317/75 (2013.01 - EP IL KR); C07K 2317/76 (2013.01 - EP IL KR)
Citation (search report)
See references of WO 2022243378A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
AU 2022276349 A1 20240104; CN 117460529 A 20240126; EP 4340943 A1 20240327; IL 308603 A 20240101; JP 2024518843 A 20240507; KR 20240007760 A 20240116
DOCDB simple family (application)
AU 2022276349 A 20220518; CN 202280036196 A 20220518; EP 22731078 A 20220518; IL 30860323 A 20231116; JP 2023571502 A 20220518; KR 20237043292 A 20220518